Vincent Ling’s Post

🔬 𝟐𝟎𝟐𝟒: 𝐀 𝐂𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐢𝐧𝐠 𝐘𝐞𝐚𝐫 𝐟𝐨𝐫 𝐏𝐫𝐞𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐂𝐑𝐎𝐬 This year has been an uphill battle for preclinical CROs. From increasing regulatory complexities and economic pressures to supply chain disruptions, the industry has faced significant hurdles. Many are feeling the strain of balancing cutting-edge research with 𝐭𝐢𝐠𝐡𝐭𝐞𝐧𝐞𝐝 𝐛𝐮𝐝𝐠𝐞𝐭𝐬 and shifting timelines. As the industry adapts to these challenges, 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩𝐬 will play a critical role in sustaining growth. Let’s continue 𝐬𝐮𝐩𝐩𝐨𝐫𝐭𝐢𝐧𝐠 each to continue advancing science for the greater good. 💡🌟 𝐈𝐭'𝐬 𝐚 𝐭𝐢𝐦𝐞 𝐭𝐨 𝐫𝐞𝐟𝐥𝐞𝐜𝐭, 𝐫𝐞𝐜𝐚𝐥𝐢𝐛𝐫𝐚𝐭𝐞, 𝐚𝐧𝐝 𝐫𝐞𝐦𝐚𝐢𝐧 𝐫𝐞𝐬𝐢𝐥𝐢𝐞𝐧𝐭. #CROs #Innovation #Resilience #Partnerships #Biotech

Fascinating changes happening in the CRO world due to a variety of causes, many specific to the individual company. Still on the whole, the reduction in early phase pharma research is having an immediate impact on the companies in the field. The question is, will we see a long-term impact with fewer novel, lifesaving drugs making it to the market?

Interesting post here from Vincent Ling on one of the lesser talked about ripple effects of the current life sciences funding landscape. While 2024 has had its share of difficulties, there's still a silver lining for CROs. Rising costs are making in-house drug development increasingly unsustainable. This reality is fueling the growth of the CRO sector. In fact, according to Fortune Business Insights, the CRO market is projected to expand from $86.33 billion in 2024 to $175.46 billion by 2032. That’s a compounded annual growth rate of 9.3%. And the good news doesn’t stop there.  WCG reports that the demand for new clinical trials is now surpassing the number of available research sites.  This mismatch is creating opportunities for CROs to step in and bridge the gap. Add to that the accelerating integration of artificial intelligence and machine learning, and the future of the CRO industry looks even brighter. It’s clear: despite the hurdles, a resurgence is on the horizon for CROs.

**Challenging Times for Pharma CROs** Since January, the preclinical contract research sector has faced significant challenges, with companies like Evotec, Wuxi Apptec, and Gingko Bioworks experiencing a sharp decline in their stock prices, ranging from 60% to 80%. Amidst this downturn, Charles River has managed to maintain stability. It is noteworthy that despite the well-publicized challenges faced by Wuxi Apptec, it has outperformed both Evotec and Gingko Bioworks, which are grappling with their own set of issues. This dramatic decrease in share prices appears to be linked to the broader contraction in big pharma headcount and layoffs. Reduced orders have led to diminished revenue and a slowdown in research activities, raising concerns about a potential vicious cycle for the contract research lab industry.

𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐍𝐞𝐰𝐬! 𝐏𝐇𝐀𝐑𝐌𝐍𝐄𝐓 𝐀𝐜𝐪𝐮𝐢𝐫𝐞𝐬 𝐌𝐎𝐍𝐈𝐏𝐎𝐋 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐆𝐦𝐛𝐇 𝐚𝐧𝐝 𝐄𝐱𝐩𝐚𝐧𝐝𝐬 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐅𝐨𝐨𝐭𝐩𝐫𝐢𝐧𝐭 We're thrilled to announce that PHARMNET has acquired MONIPOL Biotech GmbH in Hamburg, Germany, and established MONIPOL Biotech PL Sp. z o.o. in Kraków, Poland. This strategic move solidifies our position as a leading CRO in Central Europe and expands our capabilities to serve clients across Europe. By combining our expertise with MONIPOL's broad experience in clinical trials, we're now able to offer our clients a more comprehensive range of services, including: • 𝐄𝐱𝐩𝐚𝐧𝐝𝐞𝐝 𝐠𝐞𝐨𝐠𝐫𝐚𝐩𝐡𝐢𝐜 𝐜𝐨𝐯𝐞𝐫𝐚𝐠𝐞: Our expanded network of sites and KOLs allows us to recruit patients from a wider pool (150+ mil population) and streamline the clinical trial process. • 𝐄𝐧𝐡𝐚𝐧𝐜𝐞𝐝 𝐫𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐞𝐱𝐩𝐞𝐫𝐭𝐢𝐬𝐞: We now have a deeper understanding of local regulations and can navigate the regulatory landscape more efficiently. • 𝐋𝐨𝐜𝐚𝐥 𝐥𝐚𝐧𝐠𝐮𝐚𝐠𝐞 𝐬𝐮𝐩𝐩𝐨𝐫𝐭: Our in-country teams can provide support in the local language, ensuring effective communication and collaboration with investigators, patients, and other stakeholders. Want to learn more about how this acquisition can benefit your clinical research projects and what it implies for our clients and partners? Please visit our website https://lnkd.in/gHiakbVe or connect with us via 𝐛𝐝@𝐩𝐡𝐚𝐫𝐦𝐧𝐞𝐭-𝐜𝐫𝐨.𝐜𝐨𝐦. #CRO #acquisition #expansion #clinicaltrials #clinicalresearch #pharma #biotech

Hello #network! Today I want to give you a bigger picture about Pharmaron and our success story: 🌍 Global Reach: With 20,000+ experts across China, U.S., and U.K., Pharmaron pioneers R&D solutions worldwide. 🔍 Comprehensive Capabilities: From small molecules to biologics, we cover the entire drug development spectrum. 📚 Investing in Talent: Continuous learning fuels our innovation, exceeding partner expectations. 🏗️ Global Expansion: New facilities, increased capacity, and strategic acquisitions ensure cutting-edge support for our partners. 🧩 Building Success: Our logo, inspired by tangram, embodies diversity, unity, and endless possibilities in drug R&D. 🔴🔵 Symbolic Excellence: Red and blue shapes signify commitment and professional quality in molecule-biology interactions. Explore innovation with Pharmaron—where science meets success! 🔗🌟 https://www.pharmaron.com/ #PharmaronInnovation #DrugDiscovery #GlobalLeadership

𝐁𝐫𝐢𝐝𝐠𝐢𝐧𝐠 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐕𝐂 𝐀𝐭𝐭𝐫𝐚𝐜𝐭𝐬 𝐂𝐡𝐢𝐧𝐞𝐬𝐞 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 Chinese companies continue to demonstrate a strong commitment to European innovation. Recently, WuXi AppTec announced its €20M investment in Jeito Capital’s latest biopharma-focused fund highlighting this trend. WuXi AppTec is the world-leading contract research, development, and manufacturing organisation that provides comprehensive R&D and manufacturing services to the pharmaceutical, biotech, and medical device industries. It has now invested in the Jeito II fund which aims to accelerate early-stage biopharma companies addressing critical unmet clinical needs, focusing on therapies in oncology, rare diseases, and advanced treatments. This collaboration reflects the increasing interest of Chinese investors in European VC funds, particularly in sectors like biotech, where shared expertise and strategic alignment can generate significant impact. Such investments not only provide financial support but also unlock opportunities for European startups to access global markets, leverage industrial resources, and scale innovation. At Transphere Consulting we work with Chinese investors looking to bring finance and other resources to the European innovation ecosystem and connect them with opportunities here. #VentureCapital #VC #investment #China #Europe #Biotech

What do I do daily?    A big part of you could struggle to answer this question, right? And I might have the same problem with you! So, how about we reintroduce ourselves? 😉 Let me start! ➡️ What do I do? Since 2006, I've been leading a unique Contract Research Organization. Our mission is to revolutionize clinical research by delivering simpler, faster, and higher standard solutions. We collaborate mainly with pharmaceutical, biotech and medtech companies.   ➡️ Why do I do this? I firmly believe that the fusion of knowledge, experience, technology, and the passion of individuals striving for a healthier future is the cornerstone of our ability to develop products that can significantly enhance the quality and duration of life for patients. This belief is what drives me and my team at Axcellant every day.    I appreciate my LinkedIn network and I'd love to discover it more and become more active here. Feel free to join me and share your thoughts or questions about my area of specialization. Or just let me know if you are here and it is worth opening up. That would be a great motivation! 🤝

Have you signed up for this insight into the Nuts and Bolts of Small molecule INDs. come and get your questions answered from our team of Subject Matter Experts

At TCG Labs-Soleil, we're pioneering a new era of drug discovery, offering unique advantages to scientific founders, drug hunters, and the pharma and biotech industries. Our model is designed to streamline the journey from idea to clinical application. This includes: 🚀 Efficient R&D: Scientific founders gain access to a top-tier drug discovery team and dedicated funding, ensuring a smooth transition from concept to reality. 🎯 Focused Approach: We form portfolio companies around single-asset programs, emphasizing efficient development and clinical validation.  🤝Simple Transactions: Our model supports flexible, strategic partnerships, each grounded in human proof of concept and ready for seamless integration into late-stage development efforts. 🔬 One Lab, One Team: Our evergreen team model ensures continuity, focus, and productivity, allowing us to excel in what we do best – innovating for the future of healthcare. Discover how TCG Labs-Soleil can revolutionize your drug development pipeline. Learn more: https://lnkd.in/gzspeSsd #PharmaPartnerships #Founders #BiotechInnovation #TCGLabsSoleil #DrugDiscovery